|
A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) Clinical research trials and A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including A Case Controlled Etiologic Study of Sarcoidosis (ACCESS). A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) clinical trial. Participants oftentimes recieve the finest healthcare available for their A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)  A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
For Condition: Sarcoidosis,Lung Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To test specific hypotheses concerning environmental, occupational, lifestyle, and other risk factors for sarcoidosis. Also, to examine the familial aggregation of sarcoidosis and to test genetic hypotheses concerning its etiology. Finally, to describe the natural history of sarcoidosis, particularly in African-Americans who appear to be disproportionately affected, and to implement a system for storing biological specimens including blood cells, plasma, and serum.
Details: BACKGROUND: Sarcoidosis is a systemic granulomatous disorder of unknown etiology. While recognized as a distinct clinical entity for over a century, information on incidence, prevalence, risk factors, and natural history in the United States remains quite limited. Data available on the occurrence in the United States indicate that the incidence ranges from about 1 to 10 per 100,000 and prevalence from about 5 to 50 per 100,000. Incidence appears highest for young adults, ages 25 to 40, higher in females than males, and much greater in African Americans than other ethnic groups. Morbidity from this chronic disease is not well estimated by mortality data. In 1981, there were over 10,000 discharges from United States hospitals for sarcoidosis. Like mortality data, the hospital discharge information probably substantially underestimates the morbidity associated with sarcoidosis which is typically managed on an outpatient basis. The Requests for Proposals were issued in September, 1994. Awards were made in June, 1995. DESIGN NARRATIVE: Each of ten clinical centers enrolled patients with sarcoidosis. Because population-based case-finding mechanisms have not been widely implemented for sarcoidosis, an institution-based rather than a population-based design was used. Participating institutions were located in geographic regions where the disease was known and ethnic and gender factors could be addressed. Several investigator-initiated studies were carried out. In addition to etiology, ACCESS examined the socioeconomic status and clinical course of patients with sarcoidosis. Newly diagnosed cases of sarcoidosis were compared to age, sex, and race matched controls. Leads to the etiology of sarcoidosis have come from diverse sources: in clinical laboratory investigations, alveolitis has been found to precede granulomatous inflammation; in case control studies, familial aggregation has been identified; and in case reports, recurrence of granulomatous inflammation has been observed after lung transplantation.
Eligibility:
Study Type: Observational, Natural History, Case Control
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertBaughman, , University of Cincinnati
Additional Information:
Study ID Numbers: 1303;
Study Start Date: June 1995
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005276
Other Sarcoidosis Studies:
1. A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
2. Infliximab in patients with chronic sarcoidosis with pulmonary involvement
3. Role of Genetic Factors in the Development of Lung Disease
Related Studies:
Other Sarcoidosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
|
|
|
|
|
|
|
|
